Format

Send to

Choose Destination
Am J Kidney Dis. 2019 Mar;73(3):316-323. doi: 10.1053/j.ajkd.2018.09.002. Epub 2018 Nov 7.

Kidney Transplantation in C3 Glomerulopathy: A Case Series.

Author information

1
Division of Kidney Disease and Hypertension, Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC. Electronic address: rshenk@mfa.gwu.edu.
2
Division of Nephrology and Hypertension, Department of Medicine, Oregon Health and Science University, Portland, OR.
3
Division of Nephrology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY.

Abstract

RATIONALE & OBJECTIVE:

C3 glomerulopathy (C3G), a form of glomerulonephritis associated with dysregulation of the alternative complement pathway, occurs either as dense deposit disease (DDD) or C3 glomerulonephritis (C3GN). Few studies have reported outcomes of patients with C3G after transplantation since its formal classification and the advent of complement-targeting therapies such as eculizumab.

STUDY DESIGN:

Case series of C3G.

SETTING & PARTICIPANTS:

We reviewed laboratory testing, native and allograft biopsy reports, and clinical charts of the 19 patients (12, C3GN; and 7, DDD) from our C3G registry who underwent transplantation between 1999 and 2016.

RESULTS:

During a median follow-up of 76 months, 16 patients had recurrent disease (10 of 12, C3GN; and 6 of 7, DDD), with median time to recurrence of 14 months in C3GN versus 15 months in DDD. Graft failure was more frequent in patients with DDD (6 of 7) than in patients with C3GN (3 of 12), occurred at a median time of 42 months posttransplantation, and was attributed to recurrent disease in half the failures. A rare genetic variant or autoantibody associated with alternative complement pathway abnormalities was detected in 9 of 10 screened patients. Treatment of 7 patients (8 allografts) with eculizumab was associated with variable clinical outcomes.

LIMITATIONS:

Incomplete testing for complement pathway abnormalities and genetic defects, incomplete records of HLA antigen matching, lack of centralized biopsy review, and limited sample size.

CONCLUSIONS:

In a case series of C3G transplant recipients, the proportion of disease recurrence was high in both C3GN and DDD, although graft loss appeared to occur more frequently in DDD. In a small subset of study patients, eculizumab therapy was not consistently followed by salutary outcomes.

KEYWORDS:

C3 glomerulonephritis (C3GN); C3 glomerulopathy (C3G); allograft recurrence; case series; complement dysregulation; dense deposit disease (DDD); eculizumab; glomerulonephritis (GN); kidney transplantation; recurrent glomerular disease

PMID:
30413277
DOI:
10.1053/j.ajkd.2018.09.002

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center